| CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products |
41 |
| Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia |
28 |
| New and emerging therapies for acute and chronic graft versus host disease |
22 |
| Practical aspects of extended half-life products for the treatment of haemophilia |
21 |
| Epigenetic therapy combinations in acute myeloid leukemia: what are the options? |
21 |
| Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches |
20 |
| Gene therapy for hemophilia: what does the future hold? |
19 |
| Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
14 |
| Immunotherapy in myeloma: how far have we come? |
13 |
| Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy |
11 |
| Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays |
11 |
| Daratumumab in untreated newly diagnosed multiple myeloma |
11 |
| Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
11 |
| Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia |
10 |
| The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia |
10 |
| The evolution of stem-cell transplantation in multiple myeloma |
10 |
| Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia |
9 |
| The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A |
9 |
| Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? |
8 |
| Update on the role of lenalidomide in patients with multiple myeloma |
8 |
| Updates in the management of polycythemia vera and essential thrombocythemia |
7 |
| Novel insights into the treatment of complement-mediated hemolytic anemias |
7 |
| Novel therapies and current clinical progress in hemophilia A |
7 |
| The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma |
7 |
| Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia |
7 |
| Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant |
6 |
| Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist |
5 |
| Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia |
5 |
| A case series of Kimura's disease: a diagnostic challenge |
5 |
| Biomarkers in acute graft-versus-host disease: new insights |
5 |
| Recent advances in musculoskeletal physiotherapy for haemophilia |
5 |
| Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis |
4 |
| Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B |
4 |
| A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting |
4 |
| Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia |
4 |
| Eltrombopag-based combination treatment for immune thrombocytopenia |
3 |
| Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility |
3 |
| Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice |
3 |
| Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma |
3 |
| Emerging treatment options for patients with p53-pathway-deficient CLL |
3 |
| The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries |
3 |
| Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia |
2 |
| Efficacy and safety of simoctocog alfa (Nuwiq (R)) in patients with severe hemophilia A: a review of clinical trial data from the GENA program |
2 |
| Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm |
2 |
| Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations |
2 |
| Stem-cell transplantation in multiple myeloma: how far have we come? |
2 |
| Chronic myelomonocytic leukemia associated with myeloid sarcomas and NPM1 mutation: a case report and literature review |
2 |
| Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant |
2 |
| The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia |
1 |
| Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study |
1 |
